Somerset Therapeutics
India 376 employees Updated 9 July 2026
Somerset Therapeutics is a finished-dose manufacturer based in India. It appears in 84 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its most recent recorded inspection, by US FDA, closed on 21 February 2025 as OAI. Customs aggregates show $194K of exports covering 2 molecules to 2 destinations in 2025.
1
registered plants
1 with an FDA FEI number
84
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 21 February 2025 OAI US FDA
- 27 October 2023 VAI US FDA
- 4 April 2022 OAI US FDA
- 19 February 2020 OAI US FDA
- 23 July 2019 VAI US FDA
- 5 December 2017 VAI US FDA
- 24 April 2017 NAI US FDA
- 20 August 2013 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Bengaluru, India | 3003821988 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 84 | None |
Scale
| Year | Revenue | Exports | Destinations |
| 2026 YTD | Not reported | $1.5M | 2 |
| 2025 | Not reported | $194K | 2 |
| 2024 | Not reported | $82K | 2 |
| 2022 | Not reported | $45K | 2 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Comparing suppliers?
Choose your molecules and target markets. Somerset Therapeutics comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was OAI, on 21 February 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- Customs aggregates
- Export values, molecule and destination counts